Prostate-specific membrane antigen (PSMA)–negative neuroendocrine prostate cancer (PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic options. Here, FOLH1 is linked to posterior cortical atrophy.